MAM
ACAD icon

McCarthy Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

McCarthy Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,666
Closed -$40K – 36
2022
Q1 		$40K Hold
1,666
– – 0.03% 96
2021
Q4 		$39K Sell
1,666
-268
-14% -$5.39K 0.03% 100
2021
Q3 		$32K Sell
1,934
-2,597
-57% -$50.1K 0.02% 109
2021
Q2 		$111K Buy
4,531
+2,331
+106% +$52.6K 0.08% 54
2021
Q1 		$57K Sell
2,200
-1,131
-34% -$49.8K 0.04% 84
2020
Q4 		$178K Buy
+3,331
New +$165K 0.15% 34

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

McCarthy Asset Management's ACAD Position: Q2 2022 in Review

McCarthy Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2022, closing a stake of 1,666 shares — an estimated $40K sold.

McCarthy Asset Management first reported a position in ACAD in Q4 2020 and held it in 6 quarters. The position peaked at $178K in Q4 2020. 246 funds tracked by Wall St. Rank hold ACAD as of Q2 2022.

  • McCarthy Asset Management reported no remaining Acadia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • McCarthy Asset Management sold 1,666 Acadia Pharmaceuticals shares in Q2 2022, an estimated $40K.
  • McCarthy Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2020 and held it in 6 quarters.
  • McCarthy Asset Management's Acadia Pharmaceuticals position peaked at $178K in Q4 2020.
  • 246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2022.

Based on McCarthy Asset Management's 13F filing for Q2 2022, filed 20 Jul 2022.